Reata
Ultomiris gets US FDA Priority Review for immunoglobulin A nephropathy treatment
If approved, this would be the first C5 complement inhibitor available for this rare kidney disease
Game On: Medscape Education Golfs for a Cause
Medscape Education is proud to stand alongside the National Kidney Foundation (NKF) as a sponsor of one of the nation’s most impactful charity events benefiting patients living with kidney disease,...
FDA approves Apellis’ Empaveli for two rare kidney diseases
C3G and primary IC-MPGN are estimated to affect 5,000 people in the US
Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study
C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe
Otsuka shares promising phase 3 results for sibeprenlimab in rare kidney disease IgAN
The trial will continue to evaluate change in kidney function over two years
Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G
Approximately half of C3G patients progress to kidney failure within ten years of diagnosis
Biogen initiates phase 3 study of felzartamab in kidney transplant patients
The trial will evaluate the candidate in patients with antibody-mediated rejection
Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy
Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year
FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy
The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression
Sobi and Apellis’ pegcetacoplan shows promise in phase 3 rare kidney disease study
There are currently no treatments that target the underlying cause of C3G or IC-MPGN
Novartis’ Fabhalta granted FDA approval for rare kidney disease IgA nephropathy
Approximately 25 people per million worldwide are diagnosed with IgAN every year
Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy
Approximately one to two people per million worldwide are diagnosed with C3G every year